Publications

Systematic review and network meta-analysis highlight that RA patients who receive recommended doses of the five approved JAK inhibitors (tofacitinib, baricitinib, upadacitinib, filgotinib, and peficitinib) are likely to experience an increase in serum low- and high-density lipoprotein (LDL and HDL) levels.JAK inhibitors have been associated with alterations in levels of LDL and HDL cholesterol, which may lead to dyslipidaemia (an important risk factor for cardiovascular disease). However, the extent of these changes, the implications for patient safety, and the relative effect of one JAKi compared to another, remains unclear.To help address this, Li, et al. undertook a systematic review and network meta-analysis to try to estimate the effect of JAK inhibitors on LDL and HDL levels in patients with RA.